Brian Park, PharmD

Drug Information Specialist https://www.clinicalpainadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Opioid Addiction

Nalmefene HCl Injection Now Available for Opioid Overdose Treatment

Brian Park, PharmD

June 23, 2022

Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.

Neuropathic Pain

Eplontersen Meets Endpoints in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Brian Park, PharmD

June 23, 2022

Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.

General Medicine

Mixed Results for Paxlovid in Standard Risk Patients With COVID-19

Brian Park, PharmD

June 21, 2022

The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.

Interventional Pain Management

Novel 12-LOX Inhibitor Fast Tracked for Heparin-Induced Thrombocytopenia

Brian Park, PharmD

June 21, 2022

VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.

Neuropathic Pain

Vutrisiran Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Brian Park, PharmD

June 16, 2022

Amvuttra is a subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.

Neuropathic Pain

Topical Amitriptyline Granted Fast Track Status for Chemotherapy-Induced Neuropathic Pain

Brian Park, PharmD

June 14, 2022

ATX01 is a topical formulation of amitriptyline designed to directly inhibit pain signaling in the nerve fibers on the epidermis and dermis.

Musculoskeletal Pain

Rituximab Biosimilar Approved for Rheumatoid Arthritis

Brian Park, PharmD

June 10, 2022

The approval is supported by data from a phase 3 study that compared the efficacy, safety, pharmacokinetics and immunogenicity of Riabni to rituximab reference products.

Musculoskeletal Pain

Baclofen Oral Granules Now Available for Spasticity Due to Spinal Cord Disorders

Brian Park, PharmD

June 9, 2022

The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.

Next post in Musculoskeletal Pain